

**STATEMENT TO THE ANNUAL GENERAL MEETING OF  
SHAREHOLDERS 2017**

***(Ref: amendment and supplement of the Charter of  
DHG Pharmaceutical Joint Stock Company (DHG PHARMA))***

**Kind Attn to: THE GENERAL MEETING OF SHAREHOLDERS OF DHG PHARMA**

- Pursuant to the Enterprise Law 2014 and other relevant guidelines;
- Decree 71/2017/NĐ-CP dated 06 Jun 2017, effective from 01 Aug 2017(Decree 71);
- Circular 95/2017/TT-BTC guiding Decree 71/2017/NĐ-CP, effective from 06 Nov 2017 (Circular 95);
- Pursuant the Charter of Organization and Operation of DHG Pharma issued on 07 Feb 2018 (the Company's Charter),

The Board of Directors kindly submits the General Meeting of Shareholders for approval of the amendment and supplement of DHG Pharma's Charter after the merger in accordance with the reference table enclosed.

Reason for amendment and supplement:

- Updated according to Circular 95 and the Company's situation.
- Implemented the FOL lifting under Resolution No.002/2017/NQ.ĐHĐCĐ dated 28 July 2017 of the General Meeting of Shareholders and the merger plan of DHG Pharmaceutical One Member Limited Company and DHG Packaging and Printing 1 One Member Limited Company into DHG Pharma.

The legal basis of the amendment and supplement of the Company's Charter:

- Point a, Clause 2, Article 195 of the Enterprise Law 2014 stipulates: "Related companies shall prepare a merger contract and a draft Charter of the merged company.
- Article 3 of Circular 95 stipulates: A public company shall refer to the sample Charter in Annex 1 of this Circular to compile the Company's Charter, and to ensure compliance with the provisions of the Enterprise Law, the Law on Securities, Decree 71/2017/NĐ-CP, and current law.

The amendment and supplement of the Company's Charter is necessary to implement the merger plan and to ensure the provisions of the Enterprise Law 2014, Decree 71 and Circular 95.

Respectfully submits to the General Meeting of Shareholders for consideration and approval.

Best regards./.

**Recipients:**

- As above;
- Archived: BOD Secretary.

**ON BEHALF OF THE BOD  
CHAIRMAN**

**Nguyen Chi Thanh**

[NOTICE: This Convocation Notice is a translation of the Vietnamese language original for convenience purpose only, and in the event of any discrepancy, the Vietnamese language original shall prevail.]

**REFERENCE TABLE**  
**Amendments and supplements of the Charter of DHG Pharmaceutical Joint Stock Company (20<sup>th</sup> time)**  
**at the Annual General Meeting of Shareholders 2017**  
*(Attached to Statement No.005/2018/TTr.DHĐCĐ dated 12<sup>th</sup> March 2018)*

**1. Basis of supplements and amendments:**

- The Law on Enterprises No.68/2014/QH 13 dated 26 November 2014, takes effect from 01 July 2015 (shall be hereinafter referred to as LDN);
- The Decree No.71/2017/NĐ-CP dated 06 June 2017, takes effect from 01 August 2017 (shall be hereinafter referred to as ND71);
- The Circular No.95/2017/TT-BTC for a guidance on Decree No. 71/2017/NĐ-CP (shall be hereinafter referred to as TT95);
- The Sample Charter attached to Circular No.95/2017/TT-BTC (shall be hereinafter referred to as SC).

**2. Reference instruction**

Italic text: new supplements and amendments.

~~Strikethrough text: content which is recommended to eliminate.~~

**3. Contents of supplements and amendments**

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
<b>Article 2. Interpretation of term</b>	<b>Article 2. Interpretation of term</b>	
2. s. “ <del>Independent members of the Board of Directors</del> ” are the members of the Board of Directors that satisfy the following standards and conditions:	2. s. “ <u>Independent Board of Directors members</u> ” are the members of the Board of Directors that satisfy the following standards and conditions:	Article 2.7 ND 71
<b>Article 3. Name, Form, Head Office, Branch, Representative Office, and Operation Term</b>	<b>Article 3. Name, Form, Head Office, Branch, Representative Office, and Operation Term of <u>DHG PHARMA</u></b>	
1. Name of the company:	1. Name of the company:	
- <del>Vietnamese name</del> : CÔNG TY CỔ PHẦN DƯỢC HẬU GIANG	- <u>In Vietnamese</u> : CÔNG TY CỔ PHẦN DƯỢC HẬU GIANG	
- <del>Foreign name</del> (English): DHG PHARMACEUTICAL JOINT-STOCK COMPANY	- <u>In English</u> : DHG PHARMACEUTICAL JOINT-STOCK COMPANY	

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
- <del>Abbreviated name:</del> DHG PHARMA	- <u>In abbreviation:</u> DHG PHARMA	
<b>Article 5. Operational objectives of DHG PHARMA</b>	<b>Article 5. Operational objectives of DHG PHARMA</b>	
2. DHG PHARMA's <del>production and business lines:</del>	1. DHG PHARMA's <u>business lines</u> are: .....	Updated in accordance with the statement on additional business lines
<b>Article 6. Scope of business and operation</b>	<b>Article 6. Scope of business and operation</b>	
1. DHG PHARMA is permitted to plan and carry out all business activities in accordance with this Charter and the current law. Also, the Company is permitted to take appropriate measures to achieve its objectives.	1. DHG PHARMA is permitted to plan and conduct all business activities in accordance with <u>the business lines the Company disclosed on the National Business Registration Portal</u> , this Charter and in accordance with applicable law. Also, the Company is permitted to take appropriate measures to achieve the objectives of DHG PHARMA	In accordance with Article 5.1 Sample Charter (SC)
<b>Article 9. Charter capital, and founding shareholders</b>	<b>Article 9. Charter capital, and founding shareholders</b>	
4. DHG PHARMA may <del>increase</del> its charter capital upon the approval of the General Meeting of Shareholders and in accordance with the Law	4. DHG PHARMA may <u>change</u> its charter capital upon the approval of the General Meeting of Shareholders and in accordance with the Law.	According to Article 6.2 SC.
5. All shares issued by DHG PHARMA on the approval date of this Charter shall be ordinary shares. Holders of ordinary shares are referred to as common shareholders.	5. All shares issued by DHG PHARMA on the approval date of this Charter shall be ordinary shares. Holders of ordinary shares are referred to as common shareholders. <u>The rights and obligations of shareholders are stipulated in Articles 15 and 16 of this Charter.</u>	According to Article 6.3 SC.
7. Ordinary shares shall be given priority to be offered for sale to existing shareholders in proportion to the number of ordinary shares of each shareholder in DHG PHARMA unless otherwise <del>stipulated by</del> the General Meeting of Shareholders. <del>DHG PHARMA must give a notice of offer which specifies the number of shares to be offered for sale</del>	7. Ordinary shares shall be given priority to be offered for sale to existing shareholders in proportion to the number of ordinary shares of each shareholder in DHG PHARMA unless <u>decided</u> by the General Meeting of Shareholders. The number of remaining shares not subscribed to be purchased by such shareholders shall be decided by the Board of	According to Article 6.6 SC.

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
<p><del>and a time limit of not less than twenty working days so that shareholders can order for subscription.</del> The number of remaining shares not subscribed to be purchased by such shareholders shall be decided by the Board of Directors. The Board of Directors may allocate the shares to subjects in accordance with the conditions and in a manner that the Board of Directors deems appropriate, provided that the shares may not be sold on conditions which are more favourable than the conditions offered to the existing shareholders, unless otherwise approved by the General Meeting of Shareholders or in the case of shares being sold via the Stock Exchange.</p>	<p>Directors. The Board of Directors may allocate the shares to subjects in accordance with the conditions and in a manner that the Board of Directors deems appropriate, provided that the shares may not be sold on conditions which are more favourable than the conditions offered to the existing shareholders, unless otherwise approved by the General Meeting of Shareholders or in the case of shares being sold via the Stock Exchange <u>under the auction method.</u></p>	
<p><b>Article 10. Share Certificates</b></p>	<p><b>Article 10. Share Certificates</b></p>	
<p><del>2. Share certificates must be stamped by the Company and signed by the legal representative of DHG PHARMA under the provisions of the Law on Enterprises. Share certificate must specify the number and class of shares held by shareholders, the full name of the holder and other information under the provisions of the Law on Enterprises.</del></p>	<p><u>2. Shares are certificates issued by the company, book entries or electronic data certifying ownership of one or more shares of DHG PHARMA. Shares must contain all contents as stipulated in Clause 1, Article 120 of the Law on Enterprises.</u></p>	<p>According to Article 120.1 LDN and Article 7.2 SC (detailed regulation on the forms and contents of the share certificates).</p>
<p><del>5. Where a share certificate has been damaged, erased, lost, stolen or destroyed, the shareholder of this share certificate may request for a new issuance of share certificate, provided that he/she must present evidence of the ownership of shares and pay all relevant expenses to DHG PHARMA. For shares with great value, DHG PHARMA's legal representative may ask the shareholder to post a notice of shares loss and after fifteen days after publication of this notice, DHG PHARMA will be</del></p>	<p>5. If a share certificate is <u>lost, destroyed or damaged</u>, the owner of the share certificate may request a new share certificate under a condition that he/she must provide evidence of ownership and pay all relevant expenses to DHG PHARMA.</p>	<p>According to 7.4 SC. Article 120.3 LDN.</p>

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
<del>required to issue a new share certificate.</del>		
<b>Article 11. Other securities certificates</b>	<b>Article 11. Other securities certificates</b>	
1. DHG PHARMA may issue bonds, convertible bonds, and other bonds in accordance with law. The Board of Directors has the right to decide on the type of bonds, the total value of bonds and the time of issuance, but must report to the General Meeting of Shareholders in the nearest meeting. The report must be accompanied by documents and records explaining the decision of the Board of Directors on bond issuance.	1. DHG PHARMA may issue bonds, convertible bonds and other bonds in accordance with the law. The Board of Directors has the rights to decide on the types of shares ( <u>except bonds converted to shares to be decided by the General Meeting of Shareholders</u> ), the total value of bonds and the time of issuance, but must report to the General Meeting of Shareholders at the nearest meeting. The report must be enclosed with documents and dossiers explaining Board of Directors’ decision on the issuance of bonds.	Article 127.5 LDN Article 135.2b LDN
<b>Article 13. Reclamation of shares</b>	<b>Article 13. Reclamation of shares</b>	
2. The above-mentioned notice must specify a new time-limit for payment (at least seven (07) days from the date on which the notice is sent), place for payment, and clearly state that in the event that payment is not made as required, the shares which have not yet been fully paid for will be reclaimed.	2. The above-mentioned notice must specify a new time-limit for payment (at least seven (07) days from the date on which the notice is sent), place and <u>method of payment</u> , and clearly state that in the event that payment is not made as required, the shares which have not yet been fully paid for will be reclaimed.	Adding the term “method of payment” accordingly
4. The reclaimed shares shall become DHG PHARMA’s assets. The Board of Directors may directly execute or authorize the sale, redistribute or settle for persons whose own shares reclaimed or other subjects under the conditions and ways which the Board of Directors deems appropriate.	4. The reclaimed shares shall become assets and are considered as <u>the shares offered for sale of DHG PHARMA as stipulated in Clause 3, Article 111 of the Law on Enterprises</u> . The Board of Directors may directly execute or authorize the sale, redistribution or settlement for persons whose own shares reclaimed or other subjects under the conditions and ways which the Board of Directors deems appropriate.	According to Article 10.4 SC.
<b>Chapter III: ORGANIZATIONAL STRUCTURE, MANAGEMENT, AND CONTROL</b>	<b>Chapter III: ORGANIZATIONAL STRUCTURE, MANAGEMENT, AND CONTROL</b>	
<b>Article 15. Rights of shareholders</b>	<b>Article 15. Rights of shareholders</b>	

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
2. <del>Persons holding common shares</del> have the following rights:	2. <u>Common shareholders</u> have the following rights:	According to Article 12.2 SC
d. To attend and express opinions at the General Meeting of Shareholders and to exercise the right to vote directly <del>at the General Meeting of Shareholders in accordance with Clause 1 of Article 18 of this Charter;</del>	d. To attend and express opinions at the General Meeting of Shareholders and to exercise the right to vote directly <u>or through a proxy or other forms as stipulated by the law and this Charter.</u>	According to Article 114.1a LDN and Article 12.2a SC.
f. To freely transfer shares which have been fully paid for to <del>other shareholders and non-shareholders</del> in accordance with <del>this Charter</del> and the applicable law;	f. To freely transfer shares which have been fully paid for in accordance with the applicable Law; <u>except for restricted share transfer in accordance with the provisions of DHG PHARMA and applicable Law;</u>	According to Article 12.2c SC. Article 110.1d, Article 126.1 LDN.
h. To consider, consult and extract information relating to each shareholder <del>in the list of shareholders who are qualified to attend the General Meeting of Shareholders</del> and to request amendment of incorrect information;	h. To consider, consult and extract information relating to shareholders <u>with voting rights</u> and to request amendment of incorrect information;	According to Article 12.2e SC. Article 114.1d LDN
Not yet stipulated	i. <u>Access information on the list of shareholders satisfying all conditions for attending and voting at the General Meeting of Shareholders;</u>	According to Article 12.2f SC
j. In case DHG PHARMA is dissolved or bankrupt, shareholders shall receive a part of the remaining assets in proportion to the number of shares they own after DHG PHARMA paid the creditors and other classes of shareholders in accordance with the law;	k. In case DHG PHARMA is dissolved or bankrupt, shareholders shall receive a part of the remaining assets in proportion to the ownership ratio of shares in DHG PHARMA after DHG PHARMA has paid out the debts <u>(including debt obligations to the State, taxes, fees)</u> and payment to shareholders holding other classes of shares of DHG PHARMA in accordance with applicable law;	According to Article 12.2h SC. Article 114.1g LDN
3. A shareholder or a group of shareholders holding 5% or more of the total number of ordinary shares <del>from above</del> six consecutive months or more shall have the following rights:	3. A shareholder or a group of shareholders holding <u>five percents (5%)</u> or more of the total number of ordinary shares for <u>at least six (06)</u> consecutive months or more shall have the following rights:	
d. To request the Board of Supervisory to inspect each	d. To request the Board of Supervisory to inspect each	According to

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
particular issue related to the management and operation of DHG PHARMA whenever necessary. The request must be made in writing; and must contain the full name, permanent address, nationality, number of identification card, passport or other lawful personal identification in respect of a shareholder being an individual; or the name, <del>permanent address</del> , nationality, number of establishment decision or <del>number of business registration certificate</del> in respect of a shareholder being an organization; number of shares and date of registration of shares of each shareholder, total number of shares of the group of shareholders and the percentage of ownership of the total number of shares of DHG PHARMA; issues to be inspected and purpose of the inspection;	particular issue related to the management and operation of DHG PHARMA whenever necessary. The request must be made in writing; and must contain the full name, permanent address, nationality, <u>number of citizen identification/identification card/ passport</u> , or other lawful personal identification in respect of a shareholder being an individual; or the name, <u>business code or number of establishment decision</u> , <u>address of head office</u> in respect of a shareholder being an organization; number of shares and date of registration of shares of each shareholder, total number of shares of the group of shareholders and the percentage of ownership of the total number of shares of DHG PHARMA; issues to be inspected and purpose of the inspection;	142.2d LDN Article 12.3d SC.
<b>Article 16. Obligations of shareholders</b>	<b>Article 16. Obligations of shareholders</b>	
1. Shareholder shall have the following obligations:	1. Shareholders shall have the following obligations:	
	<u>g. To attend meetings of the General Meeting of Shareholders and exercise the voting right in the following forms:</u> <u>(i) to attend and vote in person at the meeting;</u> <u>(ii) to authorize others to attend and vote at the meeting;</u> <u>(iii) to attend and vote via online meetings, electronic voting or other electronic forms;</u> <u>(iv) to send votes to the meeting via mail, fax, email.</u>	Moved from Article 19.2 of the draft charter Supplemented in accordance with Article 13.2 SC
<b>Article 17. General Meeting of Shareholders</b>	<b>Article 17. General Meeting of Shareholders</b>	
2. The Board of Directors convenes the Annual General Meeting of Shareholders and selects the appropriate venue. The Annual General Meeting of Shareholders shall make decisions on issues in accordance with the law and this Charter, especially the annual financial statements and	2. The Board of Directors convenes the meeting of Annual General Meeting of Shareholders and selects the appropriate venue. The Annual General Meeting of Shareholders shall make decisions on issues in accordance with the law and this Charter, especially the annual financial statements and	According to Article 14.2 SC, Article 8.4 ND71.



Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
the <del>budgets</del> of the Company for the next fiscal year. Independent auditors shall be invited to the General Meeting of Shareholders to <del>provide advice for the approval of the annual financial statements.</del>	<u>estimation</u> of the Company for the next fiscal year. <u>In cases where the audited financial statements of DHG PHARMA have significant exceptions, DHG PHARMA may invite representatives of the independent auditing auditor to attend the General Meeting of Shareholders</u> in terms of giving explanation on <u>related</u> contents.	
3. The Board of Directors must convene the Extraordinary General Meeting of Shareholders in the following cases:	3. The Board of Directors must convene the Extraordinary General Meeting of Shareholders in the following cases:	
b. <del>The annual balance sheet</del> , semi-annual or quarterly statements or the audit reports of a fiscal year reflects the loss of half (1/2) of the equity capital in comparison with the one at the beginning of the same period;	b. <u>The annual financial statements</u> , semi-annual or quarterly statements or audited reports of a fiscal year reflect the loss of half (1/2) of the equity capital in comparison with the one at the beginning of the same period;	According to Article 14.3b SC.
c. <del>When</del> the number of the Board of Directors' members is less than the number of members required by law or less than half of the members stipulated in the Charter;	c. The number of the Board of Directors members, <u>independent Board of Directors members, supervisors</u> are less than the number of members required by law or <u>the number of the Board of Directors' members are reduced by more than one-third (1/3) compared to the number of members stipulated in this Charter;</u> d. <u>The reduced number of independent Board of Directors member does not ensure the ratio in accordance with the provisions in Clause 2 Article 32 of this Charter.</u>	According to Article 156.3a,b LDN. Article 14.3c SC.
Not yet stipulated	g. <u>Other cases in accordance with Law and this Charter.</u>	Supplemented in accordance with Article 14.3f SC.
4. To convene the Extraordinary General Meeting of Shareholders:	4. To convene the Extraordinary General Meeting of Shareholders:	
a. The Board of Directors must convene the General Meeting of Shareholders within thirty days from the date when the remaining number of members of the Board of Directors shall not satisfy the provision stipulated in	a. The Board of Directors must convene the General Meeting of Shareholders within thirty <u>(30)</u> days from the date when the member of Board of Directors, <u>independent Board of Directors member, supervisors</u> remained as	According to Article 156.3ab LDN.

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
Clause 3(c) of this Article or from the date of receipt of a request stated in Clause 3(d) or Clause 3(e) of this Article. If the Board of Directors does not convene the General Meeting of Shareholders as prescribed, then the Chairman of the Board of Directors shall be responsible before the law and must compensate to DHG PHARMA for damages arising, <del>if any</del> .	stipulated at Clause 3(c,d) of this Article or from the date of receipt of a request stated in Clause 3(f) of this Article. If the Board of Directors does not convene the General Meeting of Shareholders as prescribed, then the Chairman of the Board of Directors shall be responsible before the law and must compensate to DHG PHARMA for damages arising.	
<b>Article 18. Rights and duties of the General Meeting of Shareholders</b>	<b>Article 18. Rights and duties of the General Meeting of Shareholders</b>	
2. The Annual and Extraordinary General Meeting of Shareholders shall make decisions on the following issues:	2. The Annual and Extraordinary General Meeting of Shareholders shall make decisions on the following issues:	
c. The annual dividend payment for each class of shares in compliance with the Law on Enterprises and the rights attached to such class of shares.	c. The annual dividend payment for each class of shares in compliance with the Law on Enterprises and the rights attached to such class of shares. <u>Such dividends ratio must not be higher than the rate proposed by the Board of Directors after consulting the shareholders at the General Meeting of Shareholders;</u>	According to Article 15.2b SC.
<del>i. Reorganization, dissolution, and insolvency of DHG PHARMA;</del>	i. <u>Division, separation, consolidation, merger or conversion of DHG PHARMA;</u> j. <u>Dissolution (liquidation) of DHG PHARMA and appointment of liquidators;</u>	Amended and supplemented, separated in accordance with Article 15.2i SC Article 135.2i LDN.
3. A Shareholder shall not be permitted to vote under the following cases	3. A Shareholder shall not be permitted to vote under the following cases	
b. Repurchase of shares by such shareholder or a related person of such shareholder, except where such repurchase is implemented <del>on</del> the basis of the ratio of ownership of	b. Repurchase of shares by such Shareholder or a Related Person of such Shareholder, except where such repurchase is implemented <u>corresponding with</u> the ratio of ownership of	According to Article 15.3b SC

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
all shareholders or such repurchase is implemented via order matching or public offer on the Stock Exchange.	all Shareholders or such repurchase is implemented via <u>order matching on the Stock Exchange or public offer in accordance with the Law.</u>	
<b>Article 19. Authorized representatives</b>	<b>Article 19. Authorized representative (Proxy)</b>	
<del>2. Shareholders may attend the General Meeting of Shareholders in one of the following forms:</del>		Move this content to Article 16.1g of the draft Charter
<del>a. Directly attend the General Meeting of Shareholders;</del>		
<del>b. Send the absentee ballots by registered mail to the Board of Directors at least 01 day before the opening of the meeting. The Head of Vote Counting Committee of the General Meeting shall have the right to open the absentee ballots of such shareholders;</del>		
<del>c. Authorize others to attend the General Meeting of Shareholders. If more than one proxy is appointed, the number of shares and the number of votes of each proxy must be specified.</del>		
3. Authorization for a Proxy must be made in writing on the standard form of DHG PHARMA and must be signed in accordance with the following provisions:	2. Authorization for a Proxy must be made in writing on the standard form of DHG PHARMA and must be signed in accordance with the following provisions:	
a. If an individual shareholder is the principal, must have the signature of such shareholder and the Proxy;	a. If an individual shareholder is a principal, <u>the power of attorney</u> must be signed by such shareholder and <u>the individual/legal representative of the organization</u> authorized to attend the meeting;	According to Article 16.2a SC
b. If <del>the authorized representative</del> of a shareholder is an organization, the power of attorney must be signed by the principal, the legal representative of the organization, and their proxy to attend the General Meeting of Shareholders;	b. If an organization shareholder is a principal, <u>the power of attorney</u> must be signed by the authorized representative, the legal representative of the <u>organization shareholder</u> , and <u>the individual/legal representative of the organization</u> authorized to attend the meeting;	According to Article 16.2b SC
<b>Article 20. Change of rights</b>	<b>Article 20. Change of rights</b>	

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
<p>2. The holding of such meeting shall be valid only if there are at least two shareholders (or their proxies) and hold at least one-third of the par value of the issued shares of such class. In case there are not enough attendees as mentioned above, the meeting shall be re-organized within a period of thirty (30) days after that and the persons holding shares of such class (regardless of the number of attendees and the number of shares) who are present directly or via their authorized persons shall be deemed to constitute the quorum. At the meeting of the persons holding preference shares mentioned above, the persons holding shares of such class who are present in person or via proxies may request a secret ballot and each person when casting a secret ballot has one vote for each share of the same class.</p>	<p>2. The holding of such meeting of <u>the shareholders holding one class of preference shares to approve the above change of rights</u> shall be valid if at least <u>two (2)</u> shareholders (or their proxies) are present and hold at least <u>one-third (1/3)</u> of the par value of the issued shares of such class. In case there are not enough attendees as mentioned above, the meeting shall be re-organized within a period of <u>thirty (30)</u> days after that and the persons holding shares of such class (regardless of the number of attendees and the number of shares) who are present directly or via their authorized persons shall be deemed to constitute the quorum. At the meeting of the persons holding preference shares mentioned above, the persons holding shares of such class who are present in person or via proxies may request a secret ballot. Each <u>share of the same class shall have the equal voting rights at the meeting mentioned above.</u></p>	<p>According to Article 17.1 SC</p>
<p><b>Article 21. Convening the General Meeting of Shareholders, Agenda and Notice of meeting of the General Meeting of Shareholders</b></p>	<p><b>Article 21. Convening, Agenda and Notice of meeting of the General Meeting of Shareholders</b></p>	
<p>2. The convenor of a meeting of the General Meeting of Shareholders must carry out the following duties:</p>	<p>2. The convenor of a meeting of the General Meeting of Shareholders must carry out the following duties:</p>	
<p>a. Prepare a list of all shareholders entitled to attend the General Meeting of Shareholders no earlier <del>than ten days</del> before the <del>date of sending the invitation</del> to the General Meeting of Shareholders; the meeting agenda, and documents in accordance with the laws and regulations of DHG PHARMA;</p>	<p>a. Prepare a list of all shareholders entitled to attend the General Meeting of Shareholders no earlier than <u>five (5) days</u> before the date of sending the <u>notice of meeting</u> to the General Meeting of Shareholders;</p>	<p>Article 18.2a SC</p>
<p>Not yet stipulated</p>	<p>b. Prepare the agenda, contents of the meeting; c. Prepare documents for the meeting;</p>	<p>Supplemented in accordance with</p>

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
	d. A draft resolution of the General Meeting of Shareholders according to the proposed content of the meeting;	Article 18.2 SC
Not yet stipulated	<u>h. Other tasks to organize the Meeting</u>	Supplemented in accordance with Article 18.2g SC
<p><del>3. The notice of the General Meeting of Shareholders must include the meeting agenda and relevant information on issues to be discussed and voted on at the meeting, absentee ballots and forms of power of attorney.</del></p> <p><del>a. The notice is sent by a guaranteed method to shareholder's address and posted on DHG PHARMA's website.</del></p> <p><del>b. Sending the meeting documents and the notice of invitation specified in this clause may be substituted by posting on DHG PHARMA's website. In this case, the notice of invitation must specify where and how the document will be downloaded and DHG PHARMA must send the meeting documents to shareholders if requested by the shareholder.</del></p>	<p><u>3. The notice of the General Meeting of Shareholders is sent to all shareholders by a guaranteed method, and at the same time shall be published on the media means (website) of the Company, State Securities Committee and Ho Chi Minh City Stock Exchange.</u></p> <p><u>The convener of the General Meeting of Shareholders must send the notice of meeting to all shareholders satisfying all conditions for attending and vote at the meeting of the General Meeting of Shareholders at least fifteen (15) days prior to the opening day of the General Meeting of Shareholders, (calculated from the date on which the notice is validly sent or delivered, the postal charge is paid, or the notice is put in the mailbox). The agenda of the meeting of the General Meeting of Shareholders and documents relating to the matters to be voted at the meeting shall be sent to the Shareholders and/or published on the website of the Company. In the case where no document is attached with the notice of the meeting of the General Meeting of Shareholders, the notice inviting to the meeting must specify the website address in order to enable the Shareholders to access such documents:</u></p> <p><u>a. Meeting agenda, documents to be used in the meeting;</u></p> <p><u>b. List and detailed information on candidates in case of voting for the Board of Directors members;</u></p> <p><u>c. Votes;</u></p>	<p>Amendment is made to be in accordance with Article 18.3 SC.</p>

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
	<p>d. Power of attorney;</p> <p>e. <u>Draft resolution towards each content in the meeting agenda.</u></p>	
<p>5. A shareholder or group of shareholders <del>referred to</del> in Article 15.3 of this Charter shall have the right to <del>propose</del> any issue to be included in the agenda of the General Meeting of Shareholders. <del>The proposal</del> must be made in writing and sent to DHG PHARMA at least three business days before the opening day of the General Meeting of Shareholders. <del>The proposal</del> must contain full names of the shareholders, number, and classes of shares held by them, and the issues proposed to be included in the agenda.</p>	<p>5. A shareholder or group of shareholders <u>stipulated in</u> Article 15.3 of this Charter shall have the right to <u>make recommendation</u> on any issue to be included in the agenda of the General Meeting of Shareholders. <u>The recommendation</u> must be made in writing and sent to DHG PHARMA at least three (3) business days before the opening day of the General Meeting of Shareholders. <u>The recommendation</u> must contain full names of the Shareholders, <u>permanent address, nationality, citizen identification, ID card, passport or other personal identification to those who are individual shareholders; names, business code or establishment decision, address of head office to those who are organization shareholders;</u> number and classes of shares held by <u>shareholders</u>, and the issues <u>recommended</u> to be included in the agenda.</p>	<p>Article 18.4 SC.</p> <ul style="list-style-type: none"> <li>- Change the term “proposal” to “recommendation”</li> <li>- Adding the content of recommendation</li> </ul>
<p><b>Article 23. Conditions for conducting the General Meeting of Shareholders</b></p>	<p><b>Article 23. Conditions for conducting the General Meeting of Shareholders</b></p>	
<p>1. The General Meeting of Shareholders shall be conducted when the number of shareholders attending the meeting represents at least <del>65%</del> of the voting shares.</p>	<p>1. <u>The meeting</u> of the General Meeting of Shareholders shall be conducted when the number of shareholders attending the meeting represents at least <u>sixty five percent (65%)</u> of the <u>voting shares</u>.</p>	<p>According to Article 141.1 LDN.</p>
<p>2. In case the number of members of delegates shall not reach the sufficient quorum within thirty minutes from the time <del>set</del> for the opening of the meeting, the meeting must be reconvened within thirty days from the intended date of conducting the first meeting. The reconvened General</p>	<p>2. In case the number of members of delegates shall not reach the sufficient quorum within thirty (30) minutes from the time <u>determining</u> for the opening of the meeting, <u>the convenor of shall cancel the meeting</u>. <u>The meeting</u> of the General Meeting of Shareholders must be reconvened within</p>	<p>According to Article 141.2 LDN.</p>

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
Meeting of Shareholders shall be conducted only when the attendees are the shareholders and the proxies representing at least 51% of the voting shares.	thirty (30) days from the intended date of the <u>first meeting of the General Meeting of Shareholders</u> . The re-convened <u>meeting</u> of the General Meeting of Shareholders shall be conducted only when the attending members are the shareholders and their proxies representing <u>at least fifty one percent (51%) of total shares with voting right</u> .	
<b>Article 24. Procedures for conducting the meeting and voting at the General Meeting of Shareholders</b>	<b>Article 24. Procedures for conducting the meeting and voting at the General Meeting of Shareholders</b>	
1. <del>On the day of the General Meeting of Shareholders,</del> DHG PHARMA must perform the procedures for registration of shareholders and fulfill the registration until the shareholders entitled to attend the meeting complete the registration.	1. <u>Before the opening section</u> , DHG PHARMA must perform the procedures for registration of shareholders and fulfill the registration until the shareholders entitled to attend the meeting complete the registration.	According to Article 142.1 LDN, Article 20.1 SC.
2. Upon registration of shareholders, DHG PHARMA shall issue to each shareholder or proxy with voting rights a voting card which shall indicate registration number, full name of the shareholder, full name of the proxy and number of votes of such shareholder.	2. Upon registration of shareholders, DHG PHARMA shall issue to each shareholder or proxy with voting rights a voting card which shall indicate registration number, name ( <u>full name for individual</u> ) of the shareholder, name ( <u>full name for individual</u> ) of the proxy and number of votes of such shareholder.	According to Article 20.2 SC
Not yet stipulated	3. <u>The General Meeting of Shareholders shall discuss and vote on each issue in the meeting agenda. Voting shall be conducted by collecting voting cards which for the resolution, then collecting voting cards which against the resolution, and finally the overall number of votes for, against and abstain shall be aggregated and counted for decision making. The chairman shall announce the voting results immediately prior to the closing of the meeting, the General Meeting of Shareholders shall pass the election and voting regulations at the Meeting.</u>	According to Article 142.5 LDN Article 20.2 SC

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
<p>3. Any shareholder or proxy who <del>arrives late at the General Meeting of Shareholders</del> shall be registered immediately and shall have the right to participate and vote at the meeting. The Chairman shall not be responsible to delay the meeting so that such late shareholder may register, and the effectiveness of any voting which has already been conducted before the late shareholders attend shall not be affected.</p>	<p>4. Any Shareholder or Proxy who <u>arrives after the opening of the meeting</u> shall be registered immediately and shall have the right to participate and vote at the meeting. However, the Chairman shall not be responsible to delay the Meeting so that such late Shareholders may register, and the effectiveness of any voting which has already been conducted before the late Shareholders attend shall not be affected.</p>	<p>According to Article 20.3 SC</p>
<p>4. The Chairman of the Board of Directors shall act as Chairman of all the General Meeting of Shareholders convened by the Board of Directors. In case the Chairman is absent or is temporarily unable to work, then the remaining members shall elect one of them to act as the Chairman of the meeting.</p>	<p>5. The Chairman of the Board of Directors shall act as Chairman of all the meetings convened by the Board of Directors. In case the Chairman is absent or is temporarily unable to work, then the remaining members of <u>the Board of Directors</u> shall elect one of them to act as the Chairman of the meeting <u>by a majority vote.</u></p>	<p>According to Article 20.4 SC</p>
<p><del>5. The Chairman's decision on the orders, procedures or events arising out of the agenda of the General Meeting of Shareholders shall be final.</del></p>	<p>6. <u>The agenda and contents of the meeting must be approved by the General Meeting of Shareholders in the opening session. The program must clearly specify the time for each content in the meeting agenda.</u></p>	<p>According to Article 20.5 SC</p>
<p>8. The Chairman or Secretary of the General Meeting of Shareholders may carry out activities required to direct the conduct of the General Meeting of Shareholders in a valid and orderly manner and to enable the meeting to reflect the expectations of the majority of attendees.</p>	<p>7. The Chairman or Secretary of the General Meeting of Shareholders may carry out activities required to direct the conduct of the General Meeting of Shareholders in a valid and orderly manner and to enable the meeting to reflect the expectations of the majority of attendees.</p>	<p>Moved from Article 24.8 of the current Charter.</p>
<p>6. The Chairman of the meeting may at any time adjourn the General Meeting of Shareholders where as sufficient quorum is present to another time and to a different venue of the meeting decided by the Chairman, <del>without obtaining opinions</del> from the General Meeting of Shareholders, if the Chairman considers that:</p>	<p>8. The Chairman of the meeting may postpone the General Meeting of Shareholders when reaching <u>a consensus</u> or request of the General Meeting of Shareholders which has sufficient attendees in accordance with Clause 8, Article 142 of Law on Enterprises.</p>	<p>Amended in accordance with Article 20.7 SC. It is moved from Article 24.6 of the current Charter.</p>



Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
10. The person who convenes the General Meeting of Shareholders, after careful consideration, may take such measures <del>as the Board of Directors</del> deems appropriate:	12. The person who convenes the General Meeting of Shareholders, after careful consideration, may take appropriate measures to:	It is in accordance with Article 20.9 SC, and consistent with the context.
a. Adjust the number of attendees at the main venue of the General Meeting of Shareholders;	a. Adjust the number of attendees, <u>have seating arrangement for shareholders</u> at the main venue of the General Meeting of Shareholders;	According to Article 20.9 SC
<del>The Board of Directors</del> may have full powers to change the above measures and take all measures if necessary. The measures taken may be the issuance of entry permits or use of other options.	<u>The convener of the General Meeting of Shareholders</u> may have full powers to change the above measures and take all measures if necessary. The measures taken may be the issuance of entry permits or use of other options.	According to 142.7 LDN
<b>Article 25. Approving the decisions of the General Meeting of Shareholders</b>	<b>Article 25. Approving the decisions of the General Meeting of Shareholders</b>	
1. The decisions of the General Meeting of Shareholders shall be adopted when it is approved by a number of shareholders that represent 51% or more of all votes of attending shareholders (in the direct or authorized form) with the following issues:	1. The decisions of the General Meeting of Shareholders shall be adopted when it is approved by a number of shareholders with voting rights that represent <u>fifty one percent</u> (51%) or more of all votes of shareholders who are present in person or <u>by an authorized representative</u> at <u>the meeting</u> of General Meeting of Shareholders for the following issues:	
2. The decisions of the General Meeting of Shareholders shall be adopted when 65% or more of the total number of votes of all voting shareholders (in the direct or authorized form) agree on the following issues:	2. The decisions of the General Meeting of Shareholders shall be adopted when it is approved by a number of shareholders with voting rights that represent <u>sixty five percent</u> (65%) or more of all votes of shareholders who are present in person or <u>by an authorized representative</u> at the General Meeting of Shareholders for the following issues:	
d. Amendment and supplement of the Charter;	<u>d. Issuance, amendment, supplement of the Charter and Regulation on Internal Governance;</u>	Article 7 ND 71.
4. Voting to elect members of the Board of Directors and <del>the Board of Supervisory</del> must be implemented by the	4. Voting to elect members of the Board of Directors and the Supervisors must be implemented by the method of	Supplemented in accordance with

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
<p>method of cumulative voting, <del>under which</del> each shareholder shall have his/her total votes corresponding to the total shares he or she owns multiplied by the number of members to be elected to the Board of Directors and the Board of Supervisory, and each shareholder shall have the right to accumulate all of his or her votes for one or more candidates.</p>	<p>cumulative voting. <u>Accordingly</u>, each shareholder shall have his/her total votes corresponding to the total shares he or she owns multiplied by the number of members to be elected to the Board of Directors and the Board of Supervisory, and each shareholder shall have the right to accumulate all of his or her votes for one or more candidates. <u>Elected members of the Board of Directors, the Supervisors shall be determined in accordance with the number of votes from high to low. It is starting from the candidate with the highest number of votes until there are sufficient members as stipulated in the Company's Charter. In case where two (02) or more candidates have the same votes for the position of the last member of the Board of Directors, the Supervisors, it shall be re-elected among candidates who have the same votes or be selected in accordance with criteria of regulation/electoral rules.</u></p>	<p>Article 144.3 LDN</p>
<p><b>Article 26. Competence and procedures for opinion in the form of absentee voting to adopt <del>the decision</del> of the General Meeting of Shareholders</b></p>	<p><b>Article 26: Competence and procedures for collecting shareholders' opinions by solicitation of written consent to adopt <u>the resolution</u> of the General Meeting of Shareholders</b></p>	
<p>2. The competence and procedures for collecting shareholders' opinion in the form of absentee voting to adopt <del>the decision</del> of the General Meeting of Shareholders shall be implemented in accordance with the following provisions:  a. <del>The Board of Directors has the right to collect shareholders' opinions by solicitation of written consent to adopt the decision of the General Meeting of Shareholders at any time if deemed necessary in the interests of DHG PHARMA including the provisions of Article 25 of the</del></p>	<p>2. <u>The Board of Directors is entitled to collect shareholders' opinions by solicitation of written consent to adopt decisions of the General Meeting of Shareholders if deemed necessary for the benefits of DHG PHARMA.</u> The authority and procedures for collecting shareholders' opinions by solicitation of written consent to adopt <u>resolution</u> of the General Meeting of Shareholders shall be implemented in accordance with the following provisions:  a. <u>The Board of Directors must prepare the voting ballots,</u></p>	<p>Supplemented in accordance with Article 22.1 SC. It is moved from Point 2a of this Article.   Amended in</p>

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
<p><del>Company's Charter and other contents not contrary to the Law of Enterprises.</del></p> <p><del>b. The Board of Directors must prepare voting ballots, draft decisions of the General Meeting of Shareholders, documents explaining the draft decisions and send them to all shareholders with voting rights for at least 10 days before the deadline to resend the voting ballots. The list of shareholders sending voting ballots shall be made according to Clause 1 and 2, Article 21 of this Regulation. The requirements and methods for sending voting ballots and enclosed documents comply with the provisions of Clause 3, Article 21 of this Charter.</del></p>	<p><u>draft resolution of the General Meeting of Shareholders and explanatory documents of the draft resolution.</u></p> <p>b. The Board of Directors must ensure that documents are sent and disclosed to <u>shareholders within a reasonable time for voting, and must be sent for at least fifteen (15) days before the deadline for receipt of voting ballots. The request and the manner of sending voting ballots and enclosed documents shall be implemented in accordance with</u> Clause 3 of Article 21 of this article.</p>	<p>accordance with Article 22.2 SC.</p>
<p>3. Voting ballots must have the following main contents:</p>	<p>3. Voting ballots must have the following main contents:</p>	
<p>a. Name, address of head office, number <del>and issuing date of business registration certificate, place of business registration</del> of DHG PHARMA;</p>	<p>a. Name, address of head office, business <u>code</u> of DHG PHARMA;</p>	<p>According to Article 145.3a LDN</p>
<p>c. Full name, permanent address, nationality, ID card number, Passport or lawful identity documents if the shareholder is an individual; Name, permanent address, nationality, number of establishment decision or number of business registration certificate of the shareholder or proxy is shareholder is an organization; the number of shares of each class and number of votes of the shareholder;</p>	<p>c. Full name, permanent address, nationality, citizen identification number/ID card number/Passport or lawful identity documents if the shareholder is an individual; Name, <u>business code or number of establishment decision, address of head office if shareholder is an organization; Full name, permanent address , nationality, citizen identification number/ ID card number/ Passport or lawful identity documents if the proxy of shareholder is an organization;</u> the number of shares of each class and number of votes of the shareholder;</p>	<p>According to Article 145.3c LDN</p>
	<p><u>4. The completed voting ballots must bear the signature of the shareholder if the shareholder is an individual, or signature of the legal representative if the shareholder is an organization or individuals, legal representatives of</u></p>	<p>According to Article 22.4 SC It is moved up from point 4a of</p>

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
	<u>authorized organizations.</u>	this Article
<p>4. Shareholders may send completed voting ballots to DHG PHARMA in the following manners:</p> <p>a. By postal mail. <del>The completed voting ballots must bear the signature of the shareholder if the shareholder is an individual, or signature of the authorized representative or legal representative if the shareholder is an organization.</del> Every voting ballots sent to <del>the company</del> must be put in sealed envelopes and no person shall be entitled to open before the vote counting;</p>	<p>5. Shareholders may send completed voting ballots to DHG PHARMA in the following manners:</p> <p>a. By postal mail. The voting ballots sent to <u>DHG PHARMA</u> must be enclosed in a sealed envelope and no one is permitted to open it before the vote counting;</p>	According to Article 22.5 SC
<p>6. The minute of vote counting must be published on the website of the Company within twenty-four (24) hours <del>and</del> must be sent to shareholders within fifteen days from the date of completion of the vote counting;</p>	<p>7. The minute of vote counting must be published on the website of DHG PHARMA within <u>twenty-four (24) hours</u> or must be sent to shareholders within fifteen (15) days from the date of completion of the vote counting;</p>	According to Article 22.7 SC
<p><b>Article 27. Minutes of the General Meeting of Shareholders</b></p>	<p><b>Article 27. Minutes of the General Meeting of Shareholders</b></p>	
<p>1. The General Meeting of Shareholders must be recorded in the minutes and may be recorded or typed and stored in other electronic forms. The minutes must be written in Vietnamese, can be translated into <del>foreign languages</del>. In addition, the minutes shall have the following main contents:</p> <p>i. Signature of the Chairman and secretary.</p>	<p>1. The General Meeting of Shareholders must be recorded in the minutes and may be recorded or typed and stored in other electronic forms. The minutes must be written in Vietnamese, can be prepared in <u>English</u>. In addition, the minutes shall have the following main contents:</p> <p>i. Signature of the Chairman and secretary.</p>	
<p>The minutes that were written in Vietnamese and <del>foreign languages</del> shall have equal legal effects. In the event of any discrepancy, the contents in the Vietnamese version shall prevail.</p>	<p>The minutes that were written in Vietnamese and <u>English</u> shall have equal legal effects. In the event of any discrepancy in the minutes' contents in Vietnamese and <u>English</u>, the contents in the Vietnamese version shall prevail.</p>	
<p><b>Article 28. Demand for cancellation of <del>the decisions</del> of the General Meeting of Shareholders</b></p>	<p><b>Article 28. Demand for cancellation of <u>the resolutions</u> of the General Meeting of Shareholders</b></p>	
<p>Within ninety days from the date of receipt of the minutes of the General Meeting of Shareholders or the minute of</p>	<p>Within ninety (90) days from the date of receipt of the minutes of the General Meeting of Shareholders or the</p>	In accordance with Article 147 LDN,

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
<p>vote counting at the General Meeting of Shareholders, shareholders, <del>members of the Board of Directors, the General Director, the Board of Supervisory</del> shall have the right to request a court or an arbitration to consider and cancel a <del>decision</del> of the General Meeting of Shareholders in the following cases:</p>	<p>minutes of vote counting <u>by solicitation of written consent, shareholders or a group of shareholders as stipulated in Article 15.3 of this Charter</u> shall have the right to request a court or an arbitration to consider and cancel <u>the resolution</u> of the General Meeting of Shareholders in the following cases:</p>	<p>only shareholders or a group of shareholders in Article 114.2 LDN have the right to request the cancellation of the decisions of the General Meeting of Shareholders.</p>
<p>1. The sequence and procedures for convening the General Meeting of Shareholders did not comply with the provisions of <del>law</del> and this Charter;</p>	<p>1. The sequence and procedures for convening the meeting or <u>collecting opinions</u> of shareholders by <u>solicitation of written consent and issuing decisions of the General Meeting of Shareholders</u> did not comply with the provisions of the Law <u>on Enterprises</u> and this Charter, <u>except for the case as stipulated in Clause 2, Article 22 of this Charter;</u></p>	<p>According to Article 147.1, Article 148.2 LDN and SC</p>
<p>2. <del>The sequence and procedures for issuing a decision</del> and the content of the decision breached <del>the law</del> or this Charter.</p>	<p><u>2. The content of the resolution violates the law or this Charter.</u> <u>If the decision of the General Meeting of Shareholders is canceled under a decision of the Court or the arbitration, the convener of the General Meeting of Shareholders shall be considered to reorganize the General Meeting of Shareholders within thirty (30) days as the sequence and procedures stipulated in this Charter.</u></p>	<p>According to Article 141.2, Article 147.2 LDN and Article 24.2 SC</p>
<p><b>Article 29. Power and duties of the Board of Directors</b></p>	<p><b>Article 29. Power and <u>obligations</u> of the Board of Directors</b></p>	<p>According to Article 149.2 LDN</p>
<p>4. The rights and obligations of the Board of Directors shall be regulated by <del>law</del>, the Charter and the internal regulation of DHG PHARMA and the decision of the General Meeting of Shareholders. Specifically, the Board</p>	<p>4. The rights and obligations of the Board of Directors shall be regulated by <u>Law</u>, the Charter and the internal regulation of DHG PHARMA and the decision of the General Meeting of Shareholders. Specifically, the Board of Directors has the</p>	

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
of Directors has the following powers and <del>duties</del> :	following powers and <u>obligations</u> :	
a. Rights to propose:	a. Rights to propose:	
(iii) Propose the <del>annual</del> dividend payment and <del>determine the advance dividend</del> ; <del>organize the payment of dividends</del> ;	(iii) Propose dividend rates to be paid; <u>determine time-limit and procedures for paying dividends or dealing with losses incurred in the course of business</u> ;	According to Article 149.2o LDN and Article 27.2j SC
(iv) To propose classes of <del>shares</del> to be issued and total number of issued <del>shares</del> by class;	(iv) To propose classes of <u>stock</u> to be issued and total number of issued <u>stock</u> by class;	It is amended in accordance with Article 149.2b LDN and Article 27.2k SC
(v) Propose the issuance of <del>bonds</del> , convertible bonds, and <del>securities rights which allow the owner to purchase shares at a pre-determined price</del> ;	(v) Propose the issuance of convertible bonds and <u>warrant-linked bonds</u> ;	According to Article 27.2l SC
b. Rights to decide:	b. Rights to decide:	
(ii) <del>Decide to convene, prepare the content and organize the Annual and Extraordinary General Meeting of Shareholders</del> ;	(ii) <u>To approve the agenda and contents of documents for the meeting of the General Meeting of Shareholders</u> , convene the meeting of the General Meeting of Shareholders or <u>collect opinions for the General Meeting of Shareholders to approve the decision</u> ;	According to Article 149.2m LDN.
(iii) To decide the organizational structure of the Board of Management, functional sectors; DHG PHARMA's internal management regulations;	(iii) To decide the organizational structure of the Board of Management, functional sector; <u>To issue DHG PHARMA's internal management regulations</u> ;	According to Article 149.2n LDN.
(vi) Resolving DHG PHARMA's complaints against <del>managers</del> as well as the choice of DHG PHARMA's representative to resolve issues related to legal procedures against <del>such managers</del> ;	(vi) Resolving DHG PHARMA's complaints against <u>Enterprise Managers, Enterprise Executives</u> as well as the choice of DHG PHARMA's representative to resolve issues related to legal procedures against such <u>Enterprise Managers or Enterprise Executives</u> ;	Article 27.2e SC
(vii) Decide the offer price of bonds, <del>shares and convertible securities in case of authorization by the</del>	(vii) Decide the offer price of <u>stock and bonds of DHG PHARMA</u> ;	Amended in accordance with

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
<del>General Meeting of Shareholders;</del>		Article 149.2 d LDN
(x) Supervise, direct the General Director and Enterprise Executives to run DHG PHARMA's daily business operation;	(x) Supervise, direct the General Director and Enterprise Executives, <u>Enterprise Managers</u> to run DHG PHARMA's daily business operation;	Amended in accordance with Article 149.2 d LDN
c. Rights to decide on personnel:	c. Rights to decide on personnel:	
(i) Elect, dismiss the Chairman of the Board of Directors; designate, dismiss, sign contracts, terminate contracts with the General Director, Deputy General Director or Enterprise Executives or DHG PHARMA's representative, <del>when the Board of Directors assumes that it is for the supreme benefit of DHG PHARMA.</del> The above discharge shall not be contrary to the contractual rights of the dismissed people (if any);	(i) Elect, <u>remove</u> , dismiss the Chairman of the Board of Directors; designate, remove, sign contracts, terminate contracts with the General Director, Deputy General Director or Enterprise Executives or DHG PHARMA's representative. The above discharge shall not be contrary to the contractual rights of the dismissed people (if any); <u>decisions, salaries and other benefits of the above people; appointment of an authorized representative to join the Board of Directors, the Board of members or the General Meeting of Shareholders in other companies, decide on the remuneration and other benefits of those people;</u>	According to Article 149.2i LDN and Article 27.2c SC.
5. The Board of Directors must report to the General Meeting of Shareholders on its performances, in particular on the supervision of the Board of Directors over Enterprise Executives in the financial year. The Board of Directors' report on performance submitting to the General Meeting of Shareholders must include the following contents:	5. The Board of Directors must report to the General Meeting of Shareholders on its performances, in particular on the supervision of the Board of Directors over <u>Enterprise Managers</u> , Enterprise Executives in the financial year. The Board of Directors' report on performance submitting to the General Meeting of Shareholders must include the following contents:	
f. The results of supervision over the Enterprise Executives;	f. The results of supervision over <u>Enterprise Managers</u> , Enterprise Executives;	"Enterprise Managers" is supplemented.
Not yet stipulated	6. <u>The Board of Directors may authorize the Enterprise Executives, Enterprise Managers or other subordinates to</u>	Supplemented in accordance with

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
	<u>deal with work.</u>	Article 27.5 SC
	<u>7. When exercising their power and duties, the Board of Directors strictly abides by the provisions of law, this Charter and decisions of the General Meeting of Shareholders. In case the decision adopted by the Board of Directors contrary to the provisions of law or this Charter causing damage to DHG PHARMA, the members of the Board of Directors approving the decision must jointly bear personal responsibility for this decision and must compensate for damages to DHG PHARMA; Members who object to this decision will be exempt from liability.</u>	Moved from Article 30.10 of the current Charter.
<b>Article 29. Power and duties of the Board of Directors</b>	<b>Article 30. Remuneration, salaries and other benefits of the members of the Board of Directors</b>	Clause 6,7,8,9 of Article 29 of the current Charter are separated into Article 30.
6. Members of the Board of Directors (excluding authorized representatives) shall be entitled to remunerations for their assignments in their capacity as members of the Board of Directors. The total remuneration for the Board of Directors shall be decided by the General Meeting of Shareholders. This remuneration will be distributed to the members of the Board of Directors as agreed upon by the Board of Directors or equally divided in the case where no agreement is reached.	1. Members of the Board of Directors (excluding authorized representatives) shall be entitled to remunerations for their assignments in their capacity as members of the Board of Directors. The total remuneration for the Board of Directors shall be decided by the General Meeting of Shareholders. This remuneration will be distributed to the members of the Board of Directors as agreed upon by the Board of Directors or equally divided in the case where no agreement is reached.	
7. The total amount of remuneration, expenses, commissions, right to purchase shares and other benefits received from DHG PHARMA, its subsidiaries, affiliates and other companies in which a member of the Board of	2. The total amount of money paid to <u>each member of the Board of Directors: including</u> remuneration, expenses, commissions, right to purchase stock and other benefits received from DHG PHARMA, its subsidiaries, affiliates	It is amended in accordance with Article 28.2 SC.



Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
Directors is the capital contributor representative must be detailed in the annual report of DHG PHARMA.	and other companies in which a member of the Board of Directors is the capital contributor representative, must be detailed in the annual report of DHG PHARMA. <u>The remuneration of members of the Board of Directors must be shown separately in the Annual Financial Statements of DHG PHARMA.</u>	
8. Any member of the Board of Directors who holds any executive position (including the Chairman or Deputy Chairman), or who works in subcommittees of the Board of Directors or who performs other work which is, in the opinion of the Board of Directors, beyond the scope of normal tasks of a member of the Board of Directors, may be paid extra remuneration in the form of a lump sum wage on each time, or salary, commission, profit percentage or other form as decided by the Board of Directors.	3. Any member of the Board of Directors who holds any executive position (including the Chairman or Deputy Chairman), or who works in subcommittees of the Board of Directors or who performs other work which is, in the opinion of the Board of Directors, beyond the scope of normal tasks of a member of the Board of Directors, may be paid extra remuneration in the form of a lump sum wage on each time, or salary, commission, profit percentage or other form as decided by the Board of Directors.	
9. Members of the Board of Directors shall be entitled to reimbursement of all costs of meals, accommodation and travel and other reasonable expenses paid by them when performing their responsibilities as a member of the Board of Directors, including expenses arising out of attending the meetings of the Board of Directors or subcommittees of the Board of Directors, or the General Meeting of Shareholders.	4. Members of the Board of Directors shall be entitled to reimbursement of all costs of meals, accommodation and travel and other reasonable expenses paid by them when performing their responsibilities as a member of the Board of Directors, including expenses arising out of attending the meetings of <u>the General Meeting of Shareholders</u> , Board of Directors or subcommittees of the Board of Directors, or the General Meeting of Shareholders.	
<b>Article 30. The right to be informed of members of the Board of Directors</b>	<b>Article 31. The right to be informed of members of the Board of Directors</b>	
1. Members of the Board of Directors have the right to request the General Director, Deputy General Directors, Managers of units of <del>the Company</del> to provide information	1. Members of the Board of Directors have the right to request the General Director, Deputy General Directors, <u>Enterprise Executives</u> , Enterprise Managers of units of <u>DHG</u>	“Enterprise Executives” is supplemented as

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
and documents on the financial status and business operation of <del>the Company</del> and the units of <del>the Company</del> .	<u>PHARMA</u> to provide information and documents on the financial status and business operation of <u>DHG PHARMA</u> and the units of <u>DHG PHARMA</u> .	appropriate.
2. <del>Managers</del> are required to provide timely, complete and accurate information and documents as requested in writing by the members of the Board of Directors.	2. <u>Requested persons</u> in Clause 1 of this Article are required to provide timely, complete and accurate information and documents in writing as requested by the members of the Board of Directors.	"Enterprise Managers, Enterprise Executives" are replaced by "requested persons" in accordance with Clause 1.
<b>Article 32. Candidacy and nomination of candidates of the Board of Directors</b>	<b>Article 33. Candidacy and nomination of <u>members</u> of the Board of Directors</b>	
3. When the candidates for the Board of Directors have been identified, the information related to them must be published at least ten (10) days before the opening day of the General Meeting of Shareholders on the website of DHG PHARMA so that shareholders can find out about the candidates before voting. The candidates for the Board of Directors must have written commitments to provide truthful, accurate and reasonable information and to perform the tasks honestly, faithfully, cautiously and in the best interest of DHG PHARMA if elected as members of the Board of Directors. Information related to the candidates for the Board of Directors to be published must include at least:	3. When the candidates for the Board of Directors have been identified, the information related to them must be published at least ten (10) days before the opening day of the General Meeting of Shareholders on the website of DHG PHARMA so that shareholders can find out about the candidates before voting. The candidates for the Board of Directors must have written commitments to provide truthful, accurate and reasonable information and to perform the tasks honestly, faithfully, cautiously and in the best interest of DHG PHARMA if elected as members of the Board of Directors. Information related to the candidates for the Board of Directors to be published must include at least:	Amended in accordance with Article 25.1 SC

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
<p><del>a. Full name, date of birth;</del>  <del>b. Professional qualifications;</del>  <del>c. Work experience;</del>  <del>d. Name of the companies in which the candidates hold the position of members of the Board of Directors and other management positions;</del>  <del>e. The related interests with DHG PHARMA (if any);</del>  <del>f. Other information (if any).</del></p>	<p>a. Full name, date of birth;  b. Educational background;  c. Professional qualifications;  d. Work experience;  e. Organizations that the candidate holds the position of member of the Board of Directors and other managerial positions;  f. The related interests with DHG PHARMA (if any);  g. Assessment report on the candidate's contribution to DHG PHARMA, if the applicant is currently a member of the Board of Directors of DHG PHARMA;  h. Full name of the shareholder or group of shareholders nominating the candidate (if any);  i. Other information (if any).</p>	
<p><b>Article 34. Dismissal, removal, and addition of the members of the Board of Directors</b></p>	<p><b>Article 35. Dismissal, removal, and addition of the members of the Board of Directors</b></p>	
<p>1. Members of the Board of Directors shall be dismissed in the following cases:</p>	<p>1. Members of the Board of Directors shall be dismissed in the following cases:</p>	
<p>a. Such member is not <del>eligible</del> to be a member of the Board of Directors as stipulated in <del>Clause 1, Article 33</del> of the Charter or prohibited by law from being a member of the Board of Directors;</p>	<p>a. Such member does not meet <u>criteria and conditions</u> to be a member of the Board of Directors as stipulated in <u>Clause 1, Article 34</u> of <u>this</u> Charter or prohibited by law from being a member of the Board of Directors;</p>	<p>Article 156.1, 2 LDN</p>
<p><del>2. The Board of Directors may appoint new members of the Board of Directors to replace vacant positions and new members must be approved at the next General Meeting of Shareholders. Upon approval by the General Meeting of Shareholders, the appointment of such new member shall be deemed effective on the date appointed by the Board of Directors. And the term of this member is the remaining term of the Board of Directors. Any member of the Board</del></p>		<p>Article 156.3 LDN.  This content of Article 26 SC is deleted.</p>

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
<p><del>of Directors appointed to substitute for any position arising on the Board shall undergo a vote of confidence at the next Annual General Meeting of Shareholders.</del>  <del>In case the new members are not approved by the General Meeting of Shareholders, all decisions of the Board of Directors before the time of the General Meeting of Shareholders that is participated in voting by the alternative members of the Board of Directors shall be deemed to be effective.</del></p>		
<p>3. The appointment of members of the Board of Directors must be <del>announced</del> in accordance with the Laws of securities and securities market.</p>	<p>2. The appointment of members of the Board of Directors must be <u>disclosed</u> in accordance with the Laws of securities and securities market.</p>	<p>Words are modified accordingly.</p>
<p><b>Article 36. Meetings of the Board of Directors</b></p>	<p><b>Article 37. Meetings of the Board of Directors</b></p>	
<p>2. <del>The meetings of the Board of Directors shall be convened by the Chairman of the Board of Directors whenever necessary, but there must be at least one meeting every quarter.</del></p>	<p>2. <u>The Chairman of the Board of Directors must convene periodic meetings of the Board of Directors, prepare the meeting agenda, determine the appropriate time and venue of the meetings at least seven (07) days before the meeting date. The Chairman may convene a meeting whenever necessary, but there must be at least one (01) meeting every quarter.</u></p>	<p>According to Article 30.2 SC and Article 153.5 LDN</p>
<p>3. The extraordinary meetings: The Chairman must convene meetings of the Board of Directors, must not delay without plausible reason when one of the following subjects has written proposal to present the purpose of the meeting and the issues to be discussed:</p>	<p>3. The extraordinary meetings: The Chairman must convene meetings of the Board of Directors, must not delay without plausible reason when one of the following subjects has written proposal to present the purpose of the meeting and the issues to be discussed:</p>	
<p><del>a. The General Director or at least five Enterprise Managers;</del>  <del>b. At least two (02) members of the Board of Directors;</del>  <del>e. Chairman of the Board of Directors;</del>  <del>d. The Board of Supervisory.</del></p>	<p><u>a. The Board of Supervisory;</u>  <u>b. Independent members of the Board of Directors;</u>  <u>c. The General Director or at least five (05) Enterprise Managers;</u>  <u>d. At least two (02) members of the Board of Directors;</u></p>	<p>According to Article 153.4 LDN and Article 30.3 SC</p>

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
	e. <u>Proposal of the independent audit firm in accordance with Clause 5 of this Article.</u>	
4. <del>Meetings of the Board of Directors stipulated in Clause 3 of this Article must be conducted within fifteen working days after the request for the meeting is made.</del> If the Chairman of the Board of Directors does not accept to convene a meeting as requested, then the Chairman must be liable for any damage caused to DHG PHARMA; the person making the request <del>as referred to in Clause 3 of this Article may himself or herself</del> convene a meeting of the Board of Directors.	4. <u>The Chairman of the Board of Directors must convene a meeting of the Board of Directors within seven (7) working days from the date of receipt of the request specified in Clause 3 of this Article.</u> If the Chairman of the Board of Directors does not accept to convene a meeting as requested, then the Chairman must be liable for any damage caused to DHG PHARMA; the person making the request <u>have the right to replace the Board of Directors</u> to convene a meeting of the Board of Directors	According to Article 30.4 SC and Article 153.5 LDN.
5. In case of independent auditors' requests, Chairman of the Board of Directors must convene a meeting of the Board of Directors to discuss the audit report and the situation of DHG PHARMA.	5. In case of the request of <u>independent auditors audited the financial statements of DHG PHARMA</u> , Chairman of the Board of Directors must convene a meeting of the Board of Directors to discuss the audit report and the situation of DHG PHARMA.	According to Article 30.5 SC
6. Meeting Venue: Meetings of the Board of Directors shall be conducted at the registered address of DHG PHARMA or at another address in Vietnam or abroad as the decisions of the Chairman of the Board of Directors <del>and reaching a consensus of the Board of Directors.</del>	6. Meeting Venue: Meetings of the Board of Directors shall be conducted at the registered address of DHG PHARMA or at another address in Vietnam or abroad as the decisions of the Chairman of the Board of Directors.	In accordance with Article 153 LDN, the person who convenes the meeting shall decide time and venue of the meeting, etc and informs to other members, regardless of the opinions of remaining BOD members. It is

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
		suggested to remove " reaching a consensus of the Board of Directors."
7. Notification and agenda: Notice of meetings of the Board of Directors must be sent to the members of the Board of Directors <del>in advance</del> at least three working days before the meeting date. <del>The members</del> of the Board of Directors may deny the notice of meeting in writing. Notice of meetings of the Board of Directors shall be made in Vietnamese and fully informed of the program, time and place of the meeting, together with the necessary documents on the matters to be discussed and voted on at the Board meeting and <del>votes for the members of the Board of Directors who are unable to attend the meeting.</del>	7. Notice of meetings of the Board of Directors must be sent to the members of the Board of Directors at least three <u>(03) working days before the meeting date.</u> <u>A member of the Board of Directors</u> may deny the notice of meeting in writing, <u>this refusal may be changed or canceled in writing by such member of the Board of Directors.</u> Notice of meetings of the Board of Directors shall be made in Vietnamese (English versions may be prepared) and fully informed of the time, place of the meeting, <u>agenda, contents of issues to be conferred,</u> together with the necessary documents on the matters to be <u>conferred and voted at the meeting and votes of the members.</u>	According to Article 30.7 SC
The notice of invitation shall be sent by <del>post</del> , fax, electronic mail or other methods guaranteed to reach the address of each member of the Board of Directors, Supervisors and <del>the General Director</del> as registered with DHG PHARMA	The notice of invitation shall be sent by <u>letter</u> , fax, electronic mail or other methods guaranteed to reach the <u>contact</u> address of each member of the Board of Directors, Supervisors as registered with DHG PHARMA.	According to Article 30.7 SC
8. Minimum number of participants: Meetings of the Board of Directors may <del>only</del> be proceeded and pass decisions when at least three quarters (3/4) of the members of the Board of Directors present in person or <del>through an authorized representative.</del>	8. Minimum number of participants: Meetings of the Board of Directors may be proceeded and pass decisions when at least three quarters (3/4) of the members of the Board of Directors present in person or <u>through an authorized representative (or proxy) if approved by a majority of the Board of Directors' members.</u>	According to Article 30.8 SC According to Article 153.8 LDN.
In a case of an insufficient quorum, the meeting must be reconvened within <del>fifteen (15) days</del> from the proposed	In a case of an insufficient quorum, the meeting must be reconvened within <u>seven (07) days</u> from the proposed date	According to Article 30.8 SC.

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
date of the first meeting. The reconvened meeting shall be conducted if more than half (1/2) of the number of members of the Board of Directors attends.	of the first meeting. The reconvened meeting shall be conducted if more than half (1/2) of the number of members of the Board of Directors attends.	
12. Meetings by telephone or by other forms: A meeting of the Board of Directors may be conducted by way of a <del>conference call</del> between members of the Board of Directors when all or a number of members are at different places that each attending member is able to:	9. Meetings by telephone or by other forms: A meeting of the Board of Directors may be conducted by way of an <u>online conference between members</u> of the Board of Directors when all or a number of members are at different places that each attending member is able to:	According to Article 30.9 SC. It is moved from Clause 12, Article 36 of the current Charter.
Decisions passed at a meeting via telephone which are duly held and conducted shall take effect immediately after closing the meeting, but must be confirmed by signatures of all attending members of the Board of Directors in the meeting minutes.	Decisions passed at a meeting <u>via an online conference between members</u> which is duly held and conducted shall take effect immediately after closing the meeting, but must be confirmed by signatures of all attending members of the Board of Directors in the meeting minutes.	
10. <del>Declaration of interests</del> : Any member of the Board of Directors who directly or indirectly benefits from a contract or transaction signed or intended to be signed with DHG PHARMA and aware that he/she has an interest in such contract or transaction is responsible to disclose <del>the nature and contents of such interest</del> at the meeting where the Board of Directors considers the signing of such contract or transaction <del>for the first time</del> . Or such member must publicly announce <del>his/her related interests</del> at the first meeting of the Board of Directors to be held after such member becomes aware that he/she has or will have an interest in the <del>relevant</del> contract or transaction.	12. Any member of the Board of Directors who directly or indirectly benefits from a contract or transaction signed or intended to be signed with DHG PHARMA and aware that he/she has an interest in such contract or transaction is responsible to <u>disclose benefits</u> at the <u>first</u> meeting where the Board considers the signing of such contract or transaction. <u>In case a member of the Board of Directors is not aware that he/she and his/her related person have interest at the time a contract or transaction is signed with DHG PHARMA, such member of the Board of Directors must publicly announce the related interests at the first meeting of the Board of Directors to be held after such member becomes aware that he/she has or will have an interest in the above contract or transaction.</u>	According to Article 30.12 SC. It is moved from Clause 10 Article 36 of the current Charter.
13. A resolution by way of collection of written opinions shall be approved based on the majority consent of	13. A resolution of the Extraordinary General Meeting by solicitation of written consent shall be approved based on	According to Article 30.14 SC

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
<p>members of the Board of Directors who have voting rights. Such resolution shall have the same effect and validity as a resolution passed by <del>the members of the Board of Directors</del> at the meeting which is <del>convened and held in accordance with the normal practice.</del></p>	<p>the majority consent of members of the Board of Directors who have voting rights. Such resolution shall have the same effect and validity as a resolution approved at the meeting.</p>	
<p>Not yet stipulated.</p>	<p><u>14. The Chairman of the Board of Directors is responsible to send the minutes of the Board of Directors' meeting to the members and this minutes is the true evidence of work that has been carried out in the meetings, except there are objections to the content of the minutes within ten (10) days from the date on which the minutes is sent.</u></p>	<p>It is proposed to supplement in accordance with Article 30.15 SC</p>
<p><b>Article 38. The subcommittees of the Board of Directors</b></p>	<p><b>Article 39. The subcommittees of the Board of Directors</b></p>	<p>Amendment and supplement according to Article 31 SC</p>
<p><del>1. As it deems necessary, the Board of Directors may propose the General Meeting of Shareholders to approve the establishment of affiliated subcommittees to support its operation. The Board of Directors appoints 01 independent member of the Board of Directors as the chief of the subcommittee of nomination and remuneration. Members of the subcommittees may include one or several members of the Board of Directors and one or several external members decided by the Board of Directors.</del></p> <p>If DHG PHARMA has not established or shall not establish the subcommittee of nomination and remuneration, then the Board of Directors shall designate an independent member of the Board of Directors to help</p>	<p><u>1. As it deems necessary, the Board of Directors may propose the General Meeting of Shareholders to approve the establishment of affiliated subcommittees to support the operations of the Board of Directors, including: Strategic Subcommittee, Nomination &amp; Remuneration Subcommittee, Audit and Risk Management Subcommittee, and other subcommittees if it deems necessary.</u></p> <p>If DHG PHARMA has not established or shall not establish the Nomination &amp; Remuneration Subcommittee, then the Board of Directors shall designate an independent member of the Board of Directors to help the Board of Directors to</p>	<p>Edited the names of the subcommittees according to the actual situation of DHG PHARMA</p>



Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
the Board of Directors to carry out the nomination and remuneration activities.	carry out the nomination and remuneration activities.	
<del>2. In the performance of mandated powers, subcommittees shall comply with the provisions issued by the Board of Directors. These provisions may be adjusted or allow the admission of non-members of the Board of Directors to the above-mentioned subcommittees and allow them to vote as members of the subcommittee but: (a) must ensure that the number of external members is less than half of the total number of subcommittee's members; and (b) subcommittee's resolutions are effective only when a majority of the members attended and voted at the meeting are members of the Board of Directors.</del>	<u>2. The number of members of the subcommittee is decided by the Board of Directors, but there should be at least three (03) members including members of the Board of Directors and external members. Independent members of the Board of Directors/non-executive members of the Board of Directors should occupy a majority in the subcommittees and one of these members shall be appointed as Head of the subcommittees under the decisions of the Board of Directors. The Audit and Risk Management Subcommittee must have at least one member who is a specialist in accounting and is not a person working in the finance &amp; accounting department of DHG PHARMA. The activities of subcommittees must comply with the regulations of the Board of Directors. Resolutions of the subcommittees are effective only when a majority of the members attended and voted at the meeting are members of the Board of Directors.</u>	
Not yet stipulated	<u>3. The implementation of the decisions of the Board of Directors or of subcommittees under the Board of Directors, or of any person as a member of subcommittees of the Board of Directors must comply with the applicable laws and regulations in this Charter.</u>	
<del>3. The Board of Directors regulates the establishment, responsibilities of the subcommittees and the responsibilities of each member in detail. The subcommittees may include: policy development subcommittee, internal audit subcommittee, nomination and remuneration subcommittee, etc. Audit subcommittee must have at least one member who is a specialist in</del>	<u>4. The Board of Directors regulates the establishment, responsibilities of the subcommittees and the responsibilities of each member of the subcommittees in detail as stipulated in Clause 1 of this Article.</u>	

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
<del>accounting and is not a person working in the finance &amp; accounting department of DHG PHARMA</del>		
<b>Article 39. Person in charge of corporate governance of DHG PHARMA</b>	<b>Article 40. Person in charge of corporate governance of DHG PHARMA</b>	
1. The Board of Directors must nominate at least 01 person to be in charge of corporate governance of DHG PHARMA. The person in charge of corporate governance of DHG PHARMA can take over the position as DHG PHARMA secretary as specified in <del>Article 40</del> of this Charter.	1. The Board of Directors must nominate at least one (01) person to be in charge of corporate governance of DHG PHARMA. The person in charge of corporate governance of DHG PHARMA can take over the position as DHG PHARMA Secretary as specified in <u>Article 41</u> of this Charter.	
Not yet stipulated	<u>The term of the person in charge of corporate governance of DHG PHARMA is decided by the Board of Directors, up to five (05) years.</u>	Supplemented in accordance with Article 32.1 SC.
Not yet stipulated	<u>4. The Board of Directors may remove the person in charge of corporate governance of DHG PHARMA when necessary, but not in contravention of the applicable labor laws. The Board of Directors may appoint an Assistant of the person in charge of corporate governance of DHG PHARMA from time to time.</u>	Supplemented in accordance with Article 32.3 SC
<b>Article 41. Organization of management apparatus</b>	<b>Article 42. Organization of executive apparatus</b>	
DHG PHARMA promulgates an organizational system of executive management in which the Executive Board shall be responsible for and under the management of the Board of Directors. The Executive Board of DHG PHARMA has a General Director, some Deputy General Directors, a Chief Accountant and the Enterprise Executives who are appointed by the Board of Directors. The General Director and Deputy General Directors may concurrently hold the position of the members of the Board of Directors, that are appointed, dismissed or removed through a legitimate	DHG PHARMA promulgates an organizational system of executive management in which the Executive Board shall be responsible for and under the management, <u>direction, and supervision</u> of the Board of Directors. The Executive Board of DHG PHARMA has a General Director, some Deputy General Directors, a Chief Accountant and the Enterprise Executives who are appointed by the Board of Directors. The General Director and Deputy General Directors may concurrently hold the position of the members of the Board of Directors, that are appointed, dismissed or removed	"Direction, supervision" is supplemented in accordance with the Board of Directors' jurisdiction.

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
ratified resolution by the Board of Directors.	through a legitimate ratified resolution by the Board of Directors.	
<b>Article 42. Enterprise Executives</b>	<b>Article 43. Enterprise Executives</b>	
1. At the request of the General Director and approval of the Board of Directors, DHG PHARMA <del>shall be permitted</del> to recruit the Enterprise Executives as needed with the quantity and <del>quality</del> consistent with the structure and <del>practice</del> of DHG PHARMA <del>management</del> proposed by the Board of Directors from time to time. The Enterprise Executives must have the necessary diligence for the operations and organization of DHG PHARMA to achieve the objectives.	1. At the request of the General Director and upon approval of the Board of Directors, DHG PHARMA <u>is permitted to recruit and appoint the Enterprise Executives with the quantity and standard</u> as needed, consistent with the structure and management <u>regulations of</u> DHG PHARMA. The Enterprise Executives must have the necessary diligence for the operations and organization of DHG PHARMA to achieve the objectives.	Amended in accordance with Article 34.1 SC.
<b>Article 43. The General Director</b>	<b>Article 44. The General Director</b>	
<del>1. Appointment: The Board of Directors shall appoint a member of the Board or another person to be the General Director and shall enter into a contract which shall specify the salary, remuneration, benefits and other terms related to the recruitment. The information about salary, allowances and benefits of the General Director must be reported at the Annual General Meeting of Shareholders and must be itemized in the annual report of DHG PHARMA.</del>	<u>1. Appointment: The Board of Directors shall appoint one (01) member of the Board of Directors or another (01) person to be the General Director; sign a contract which shall specify the salary, remuneration, benefits and other terms. The remuneration, salary, and other benefits of the General Director must be reported at the Annual General Meeting of Shareholders, expressed in separate items in the Annual financial statements, and stated in the Annual Report of DHG PHARMA.</u>	Amended in accordance with Article 35.1 SC.
4. The General Director has the following powers and responsibilities:	4. The General Director has the following powers and <u>obligations:</u>	Changed from the word “responsibilities” to “obligations” in accordance with Article 157.3 LDN.
<b>Article 44. The Deputy General Directors</b>	<b>Article 45. The Deputy General Directors</b>	

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
2. The Deputy General Director has the following powers and obligations:	2. The Deputy General Director has the following powers and obligations:	
f. Complying with obligations of <del>Enterprise Managers</del> prescribed in Section D Chapter III of this Charter and provisions of law.	f. Complying with obligations of Enterprise Managers as stipulated in <u>Article 160 of the Law on Enterprises, Enterprise Executives</u> prescribed in Section D Chapter III of this Charter and provisions of law.	The Deputy General Director is the Enterprise Manager and Enterprise Executive as stipulated in Article 2.1m,n of the Charter
<b>Article 45. The Chief Accountant</b>	<b>Article 46. The Chief Accountant</b>	
1. A Chief Accountant is appointed, hired or recruited by the Board of Directors.	1. A Chief Accountant is <u>recruited, appointed or hired</u> by the Board of Directors.	Words are rearranged accordingly.
2. A Chief Accountant has the following powers and obligations:	2. A Chief Accountant has the following <u>responsibilities</u> and powers:	Article 55.1 of Accounting Law 2015
1. Complying with obligations of <del>Enterprises Managers</del> stipulated in Section D Chapter III of this Charter and <del>provisions</del> of law for Chief Accountant.	m. Complying with other obligations, responsibilities <u>of the Chief Accountant, Enterprise Executives</u> of DHG PHARMA in accordance with the provision of law and Chapter III of Section D of this Charter.	The Chief Accountant is the Enterprise Executive in accordance with Article 2.1n of the Charter
<b>Section D: RESPONSIBILITIES AND DUTIES OF ENTERPRISE MANAGERS</b>	<b><u>SECTION D: RESPONSIBILITIES OF MEMBERS OF THE BOARD OF DIRECTORS, GENERAL DIRECTOR AND ENTERPRISE EXECUTIVES</u></b>	
<b>Article 46. Responsible of prudence for members of the Board of Directors, the Supervisors, the General</b>	<b>Article 47. Responsibility to be prudent</b>	Article 39 SC

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
<del>Director and the Enterprise Executives</del>		
<b>Article 49. Transactions with shareholders, Enterprise Managers, and their related persons</b>	<b>Article 50. Transactions with shareholders, Enterprise Managers, <u>Enterprise Executives</u> and their related persons</b>	“Enterprise Executives” is supplemented in accordance with Article 40.5 SC.
4. DHG PHARMA must not make the following transactions unless they are approved by the General Meeting of Shareholders:	4. DHG PHARMA must not make the following transactions unless they are approved by the General Meeting of Shareholders:	
a. Grant of loans or guarantees to the Members of the Board of Directors, Supervisors, General Director, Enterprise Managers and the individuals and organizations related to them, unless DHG PHARMA and organizations related to its shareholders are companies in the same group or companies operating in a group of companies including parent companies - subsidiaries, economic groups, and the relevant law specifies otherwise.	a. Grant of loans or guarantees to the Members of the Board of Directors, Supervisors, General Director, Enterprise Managers, <u>Enterprise Executives</u> and the individuals and organizations related to them, unless DHG PHARMA and organizations related to its shareholders are companies in the same group or companies operating in a group of companies including parent companies - subsidiaries, economic groups, and the relevant law specifies otherwise.	
b. Any transaction that has the total value of 25% or more of the total value of assets recorded in the latest financial statement of DHG PHARMA between DHG PHARMA and one of the following entities:	b. Any transaction that has the total value of twenty five percent (25%) or more of the total value of assets recorded in the latest financial statement between DHG PHARMA and one of the following entities:	
(i) Members of the Board of Directors, Supervisors, General Director, Enterprise Managers and their related persons;	(i) Members of the Board of Directors, Supervisors, General Director, Enterprise Managers, <u>Enterprise Executives</u> and their related persons;	
Not yet stipulated.	<u>6. The contract or transaction in Clause 4,5 of this Article is considered by an independent consultant to be fair and reasonable in all respects in relation to the shareholders of DHG PHARMA at the time of this transaction or contract is</u>	Supplemented in accordance with Article 40.5c SC

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
	<p><u>approved by the Board of Directors or the General Meeting of Shareholders.</u>  <u>Members of the Board of Directors, General Director, Enterprise Executives, Enterprise Managers and other organizations and individuals related to the above members must not use DHG PHARMA's information which has not yet been permitted to be disclosed, or must not disclose information to others in order to implement related transactions.</u></p>	
<p><b>Article 52. The Board of Supervisory</b></p>	<p><b>Article 53. The Board of Supervisory</b></p>	
<p>1. The Board of Supervisory has the following powers and responsibilities:</p>	<p><u>1. The Board of Supervisory has the powers, obligations, and responsibilities stipulated in Article 165 of the Law on Enterprises, related laws, this Charter, including, but not limited to the following powers, obligations and responsibilities:</u></p>	<p>The word “obligation” is added in accordance with Article 165 LDN</p>
<p>c. Monitoring the financial status of DHG PHARMA, legitimacy of the activities of members of the Board of Directors, the General Director, Enterprise Executives, coordination in operation between the Board of Supervisory and the Board of Directors, the General Director and shareholders;</p>	<p>c. Monitoring the financial status of DHG PHARMA, legitimacy of the activities of members of the Board of Directors, the General Director, <u>Enterprise Managers</u>, Enterprise Executives; coordination in operation between the Board of Supervisory and the Board of Directors, the General Director, <u>Enterprise Managers</u>, <u>Enterprise Executives</u>, and shareholders;</p>	<p>“Enterprise Managers” is added accordingly. Article 38.1c SC</p>
<p>d. In case of detecting violation against regulations of law or the Charter committed by members of the Board of Directors, the General Director and Enterprise Executives, it must be notified in written text to the Board of Directors within 48 hours and ask the offenders to stop the violation and find solutions to tackle;</p>	<p>d. In case of detecting violation against regulations of law or <u>this Charter</u> committed by members of the Board of Directors, the General Director, and <u>Enterprise Managers</u>, Enterprise Executives, it must be notified in written text to the Board of Directors within <u>forty eight (48) hours</u> and ask the offenders to stop the violation and find solutions to tackle;</p>	<p>“Enterprise Managers” is added accordingly. Article 38.1d SC</p>

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
3. During the meetings of the Board of Supervisory, the Board of Supervisory may request members of the Board of Directors, <del>members of the Board of Management</del> , Internal Audit members and independent auditors to participate and respond to the issues that the Board of Supervisory concerns.	3. During the meetings of the Board of Supervisory, the Board of Supervisory may request members of the Board of Directors, <u>the General Director, Enterprise Executives</u> , Internal Audit members and independent auditors to participate and respond to the issues that the Board of Supervisory concerns.	Words are amended accordingly because Article 14 of this Charter does not regulate that the organizational structure of DHG PHARMA has the Board of Management.
4. The reports on the operation of the Board of Supervisory at the General Meeting of Shareholders must have at least the following contents:	4. The reports on the operation of the Board of Supervisory at the General Meeting of Shareholders must have at least the following contents:	
d. The results of the supervision over the members of the Board of Directors, <del>members of the Board of Management</del> , Enterprise Managers and Enterprise Executives;	d. The results of the supervision over the members of the Board of Directors, <u>the General Director</u> , Enterprise Managers and Enterprise Executives;	Words are amended accordingly.
e. The assessment report of the collaboration between the Board of Supervisory and the Board of Directors, <del>the Board of Management</del> and shareholders.	e. The assessment report of the collaboration between the Board of Supervisory and the Board of Directors, <u>the General Director, other Enterprise Managers, Enterprise Executive,</u> and shareholders.	Article 38.1c SC is applied.
5. The total remuneration of Supervisors is decided by the General Meeting of Shareholders every year. The remuneration may be higher according to the decision of the General Meeting of Shareholders. <del>The members of the Board Supervisory</del> will also be paid the travel expenses, <del>accommodation expenses</del> , and reasonable expenses when they attend meetings of the Board of Supervisory or	5. The total remuneration of Supervisors is decided by the General Meeting of Shareholders every year. The remuneration may be higher according to the decision of the General Meeting of Shareholders. <u>The Supervisors</u> will also be paid the travel expenses, <u>costs of meals, accommodation</u> , and reasonable expenses when they attend meetings of the Board of Supervisory or meetings related to the business	Words are amended accordingly.

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
meetings related to the business activities of DHG PHARMA.	activities of DHG PHARMA.	
<b>Article 53. The Supervisors</b>	<b>Article 54. The Supervisors</b>	
2. The Board of Supervisory shall elect one of the supervisors as its Head. The Head of the Board of Supervisory must be a professional auditor or accountant working full time at DHG PHARMA. The Head of the Board of Supervisory shall have the following powers and responsibilities:	2. The Supervisors elect one (01) member amongst them to act as the Head <u>by a majority vote</u> . The Head of the Board of Supervisory must be a professional accountant or auditor and must work full time at DHG PHARMA. The Head of the Board of Supervisory has the following powers and responsibilities:	The method for electing the Head of the Board of Supervisory is supplemented in accordance with Article 163.2 LDN.
b. Requesting <del>DHG PHARMA</del> to provide relevant information to report to the members of the Board of Supervisory;	b. Requesting <u>the Board of Directors, the General Director, Enterprise Managers and Enterprise Executives</u> to provide relevant information to report to the members of the Board of Supervisory;	Specified the subjects that the Board of Supervisory has the right to request.
3. <del>Members of the Board of Supervisory</del> are appointed by the General Meeting of Shareholders and the term of <del>the Board of Supervisory</del> is five (05) years; Supervisors may be elected at the Annual General Meeting of Shareholders with unlimited terms by accumulative voting.	3. <u>The Supervisors</u> are elected by the General Meeting of Shareholders and the term of <u>the Supervisors</u> is five (05) years; Supervisors may be re-elected at each General Meeting of Shareholders with unlimited terms by accumulative voting.	Words are amended and supplemented in accordance with Article 144.3 LDN
4. The Supervisors have the following standards and conditions:	4. The Supervisors have the following standards and conditions:	
a. Having full civil act capacity and not being prohibited from establishing and managing enterprises under the provisions of <del>this Law</del> ;	a. Having full civil act capacity and not being prohibited from establishing and managing enterprises under the provisions of <u>Law on Enterprises</u> ;	“Law on Enterprises” is written in detail.
<b>Article 56. Responsibility of Supervisors</b>	<b>Article 57. Responsibilities of Supervisors</b>	
<b>Article 59. The right to access information and the independence of Supervisors</b>	<b>Article 60. The right to access information and the independence of Supervisors</b>	



Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
1. The Supervisors may access all the information and records related to DHG PHARMA’s operation. Details are as follows:	1. The Supervisors may access all the information and records related to DHG PHARMA’s operation. Details are as follows:	
a. The Board of Directors, members of the Board of Directors, the General Director, Enterprise Managers shall provide full, accurate and timely information and records on the management, operation and business performance of DHG PHARMA as the request of the Board of Supervisory, unless other decisions decided by the General Meeting of Shareholders.	a. The Board of Directors, members of the Board of Directors, the General Director, Enterprise Managers <u>and Enterprise Executives</u> must provide full, accurate and timely information and records on the management, operation and business performance of DHG PHARMA as the request of the Board of Supervisory, unless other decisions decided by the General Meeting of Shareholders.	“Enterprise Executives” is added accordingly.
<b>Article 63. Annual, semi-annual and quarterly reports</b>	<b>Article 64. Annual, semi-annual and quarterly reports</b>	
1. At the end of fiscal year, the Board of Directors must prepare the following reports and records:	1. At the end of fiscal year, the Board of Directors must prepare the following reports and records:	
b. Financial statements;	b. <u>Audited</u> financial statements;	Supplemented in accordance with Article 170.2 LDN
2. DHG PHARMA must prepare annual financial statements in accordance with the provisions of the law as well as those of the State Securities Commission and such statement must be audited in accordance with <del>Article 64</del> of this Charter, and within 90 days from the date of ending each fiscal year, must submit annual financial statements which have been approved by the General Meeting of Shareholders to the competent taxation authority, the State Securities Commission, the Stock Exchange and the business registration authority.	2. DHG PHARMA must prepare the annual financial statements in accordance with the provisions of the law as well as those of the State Securities Commission and such statements must be audited in accordance with the provision of <u>Article 66</u> of this Charter, and within 90 days from the date of ending each fiscal year, must submit annual financial statements which have been approved by the General Meeting of Shareholders to the competent taxation authority, the State Securities Commission, the Stock Exchange and the business registration authority.	
The annual financial statements must include reports on the results of business and production activities which reflect truthfully and objectively the <del>profit and loss</del> situation of DHG PHARMA in the fiscal year, a balance	The annual financial statements must include an income statement which reflect truthfully and objectively the <u>profit/loss</u> situation of DHG PHARMA in the fiscal year, a <u>financial status report</u> which reflects truthfully and	Words are amended in accordance with Article 48.2 SC.

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
sheet which reflects truthfully and objectively the activities of DHG PHARMA up to date of preparing such report, a cash flow statement and explanatory notes to the financial statements. If DHG PHARMA is a parent company, it is essential to prepare not only the annual financial statements but also a consolidated balance sheet on the operation of DHG PHARMA and its subsidiaries at the end of each fiscal year.	objectively the activities of DHG PHARMA up to the date of preparing such report, a cash flow statement and explanatory notes to the financial statements. If DHG PHARMA is a parent company, it is essential to prepare not only the annual financial statements but also a consolidated balance sheet on the operation of DHG PHARMA and its subsidiaries at the end of each fiscal year.	
3. DHG PHARMA must prepare semi-annual and <del>quarterly</del> reports in accordance with the regulations of the State Securities Commission and submit them to the State Securities Commission and the Stock Exchange.	3. DHG PHARMA must formulate <u>and disclose the audited semi-annual (6-month) financial statements and quarterly financial statements</u> in accordance with the regulations of the State Securities Commission, the Stock Exchange <u>and submit them to the relevant taxation authority and the business registration authority in accordance with the Law on Enterprises.</u>	According to Article 48.3 SC
4. A summary of the annual audited financial statements must be sent to all shareholders and be published in the local newspaper and a central economic newspaper for three consecutive issues. The audited financial statements, quarterly and semi-annual statements of DHG PHARMA must be disclosed on the DHG PHARMA's website.	4. <u>The annual audited financial statements, quarterly financial statements and audited semi-annual (6-month) statements of DHG PHARMA must be disclosed on the DHG PHARMA's website.</u>	According to Article 48.4 SC
5. Interested organizations or individuals shall be entitled to examine or copy the annual audited financial statements and the semi-annual and <del>quarterly reports</del> during the working hours of DHG PHARMA at the head office of DHG PHARMA, and shall be required to pay a reasonable amount of copying fees.	5. Interested organizations or individuals shall be entitled to examine or copy the annual audited financial statements and the <u>audited</u> semi-annual (6-month) statements and quarterly financial statements during the working hours at the head office of DHG PHARMA, and shall be required to pay a reasonable amount of copying fees.	According to Article 48.5 SC
Not yet stipulated	<b><u>Article 65. Annual report</u></b> 1. <u>DHG PHARMA must disclose information on corporate governance at the Annual General Meeting of Shareholders</u>	According to Article 30 ND71 and Article 49 SC.

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
	<p>and in the Annual Report in accordance with the provisions of the Law on Securities on information disclosure.</p> <p>2. <u>DHG PHARMA is obliged to report every six (06) months and disclose information on corporate governance in accordance with the provisions of the Law on Securities on information disclosure.</u></p>	
<b>Article 64. Auditing</b>	<b>Article 66. Auditing</b>	
<p>1. <del>At</del> the Annual General Meeting of Shareholders, an independent auditing firm which is legally operating in Vietnam and is approved by the State Securities Commission shall be selected to <del>conduct</del> DHG PHARMA audit for the next fiscal year on the basis of the terms and conditions as agreed with the Board of Directors.</p>	<p>1. The Annual General Meeting of Shareholders shall appoint or <u>approve the list and authorize the Board of Directors to appoint</u> an independent auditing firm which is legally operating in Vietnam and is approved by the State Securities Commission to audit listed companies, to <u>audit the financial statements</u> of DHG PHARMA for the next fiscal year on the basis of the terms and conditions as agreed with the Board of Directors.</p>	According to Article 50.1 SC
<b>Article 67. Information disclosure and public notice</b>	<b>Article 69. Information disclosure and public notice</b>	
<p>3. Information disclosure on the income of the General Director</p>	<p>3. Information disclosure on the income of the General Director</p>	
<p>The salary of the General Director and Enterprise Managers must be shown separately in the annual financial statements of <del>the Company</del> and be reported at the Annual General Meeting of Shareholders.</p>	<p>The salary of the General Director, <u>Enterprise Managers, and Enterprise Executives</u> must be shown separately in the annual financial statements of <u>DHG PHARMA</u> and be reported at the Annual General Meeting of Shareholders.</p>	Article 31 ND71
<p>5. Information disclosure</p>	<p>5. Information disclosure</p>	
<p>Not yet stipulated</p>	<p><u>a. The Board of Directors base on the provisions of Law on Securities, the guiding documents and this Charter to elaborate and promulgate the regulation on information disclosure.</u></p>	Supplemented in accordance with Article 33.1 ND 71
<b>Chapter VIII: INTERNAL DISPUTE SETTLEMENT, TERMINATION OF OPERATION AND LIQUIDATION</b>	<b>Chapter VIII: INTERNAL DISPUTE SETTLEMENT, TERMINATION OF OPERATION AND LIQUIDATION</b>	

Current contents	Recommended contents for supplements and amendments	Interpretation of supplements and amendments
<b>Article 76. Internal dispute settlement</b>	<b>Article 78. Internal dispute settlement</b>	
1. When any dispute <del>or</del> complaint relating to <del>the Company's</del> activities <del>or</del> the shareholders' rights arising out of the Charter or any rights or obligations stipulated in the Law on Enterprises or other laws or the administrative regulations, between:	When any dispute, complaint relating to <u>DHG PHARMA's</u> activities, the rights and obligations of shareholders as stipulated in the Law on Enterprises, other <u>provision of laws, this Charter</u> , other regulations between:	According to Article 55.1 SC
The related parties will try to resolve such dispute through negotiation and reconciliation. Except where such dispute concerning the Board of Directors or the Chairman of the Board of Directors, the Chairman will preside over the settlement of disputes and shall require each party to present <del>the actual factors</del> relating to the dispute within thirty working days from the date of the arising. If the conflict concerns the Board of Directors or the Chairman of the Board of Directors, either party may request <del>the Board of Supervisory</del> to appoint an independent expert who shall <del>act as an arbitrator</del> for the dispute resolution.	The related parties will try to resolve such dispute through negotiation and reconciliation. Except where such dispute concerning the Board of Directors or the Chairman of the Board of Directors, the Chairman will preside over the settlement of disputes and shall require each party to present <u>the information</u> relating to the dispute within <u>thirty (30)</u> working days from the date of the arising. If the conflict concerns the Board of Directors or the Chairman of the Board of Directors, <u>the parties may request the Board of Supervisory</u> to appoint an independent expert who shall <u>act as a mediator</u> for the dispute resolution.	According to Article 55.1 SC According to Article 12.1 of Decree 22/2017/NĐ-CP on commercial mediation.
<b>Article 79. Liquidation</b>	<b>Article 81. Liquidation</b>	
3. Proceeds from the liquidation shall be disbursed in the following order:	3. Proceeds from the liquidation shall be disbursed in the following order:	
b. Salaries and insurance expenses for employees;	b. <u>Unpaid wages, severance allowances, social insurance and other benefits of employees under the signed collective labor agreements and labor contracts;</u>	According to Article 54.3b SC

Acting General Director

Doan Dinh Duy Khuong

12<sup>th</sup> March, 2018  
Prepared by

Vo Hoang Tam

[NOTICE: This Convocation Notice is a translation of the Vietnamese language original for convenience purpose only, and in the event of any discrepancy, the Vietnamese language original shall prevail.]